Q1e sales SEK 43m, down 2% y-o-y, adj. EBIT SEK 0m (0m) Tough comps due to Duni product-launch inven...
Q1e sales SEK 33.2m, up 25% y-o-y, EBIT margin 33.8% (24.
Redeye briefly comments on Circio’s rights issue. We pause our coverage.
Sales +7% and EBIT +11% vs. ABGSCe Organic growth of +10%, better than ABGSCe +3% Order bookings bea...
Redeye reinforces its view of Vertiseit following a solid Q1 report, with slightly higher ARR growth...
Raute reports Q1 results on May 3. We estimate earnings to improve over the course of the year, driv...
Redeye comments on Medrave's new contract with VGR.
Ahead of NoHo Partners' Q1 report, we leave our estimates largely intact.
Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibit...
Ny styrelse inför split GIG har tagit ytterligare ett steg inför den stundande spliten och utsett en...
Inför Q1-rapporten räknar Analysguiden med en lägre omsättning, drivet av konjunkturen och avyttring...
A leading consolidator in a steadily growing, fragmented market Capital-light growth, margin expansi...
Atria is currently ramping up its EUR 160m poultry investment in Finland.
Q1e to mark low point amid organic decline... ...but we expect solid earnings development in subsequ...
Redeye returns with an update following Annexin’s Q1 report, which offered no surprises.
Redeye comments today's news about the collaboration with MedHelp Care, which operates one of the mo...
The main focus on the report will be on the progress regarding the start of production for Hella and...
Redeye leaves its comments following a few press releases from Acarix in the past few days.
The internal DISA program is based on the TREX1 inhibition pathway, which potentially supports the e...
Tekniska förändringar hos Google Under Q1 och inledningen av Q2 har det genomförts en större uppdate...
